This guideline aims to provide information, based on clinical evidence, to assist clinicians who manage women with polycystic ovary syndrome (PCOS) in advising these women about the long-term health consequences of the syndrome.
Objective: To develop and translate rigorous, comprehensive evidence-based diagnosis, assessment and treatment guidelines, to improve the lives of women with polycystic ovary syndrome (PCOS) worldwide.
Objective: To evaluate the efficacy and adverse events of fezolinetant for treating vasomotor symptoms (VMS) of menopause.
The clinical course of autosomal dominant polycystic kidney disease (ADPKD) starts in childhood. Evidence of the beneficial impact of early nephron-protective strategies and lifestyle modifications on ADPKD prognosis is accumulating.
We performed a systematic review and meta-analysis of the effects of obesity ± overweight and weight loss on the corrected...
Background: The V2 receptor antagonist tolvaptan is prescribed to patients with autosomal dominant polycystic kidney disease to slow disease progression. Tolvaptan may alter BP via various acute and chronic effects.
Autosomal recessive polycystic kidney disease (ARPKD) is a hepatorenal fibrocystic disorder that is characterized by enlarged kidneys with progressive loss of renal function and biliary duct dilatation and congenital hepatic fibrosis that leads to portal hypertension in some patients.
Background: In autosomal dominant polycystic kidney disease (ADPKD), cyst development and enlargement lead to ESKD. Macrophage recruitment and interstitial inflammation promote cyst growth.
Objectives: This study aims to systematically review the literature to determine whether a staged or simultaneous approach to native nephrectomy in ADPKD is the optimal approach in terms of morbidity and graft outcomes.
Purpose of review: Obesity is a major risk factor for the development of de novo chronic kidney disease (CKD). However, once kidney disease is acquired, obesity is paradoxically linked with greater survival, especially in those with advanced CKD.